CAS 378-44-9|Betamethasone
Introduction：Basic information about CAS 378-44-9|Betamethasone, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Betamethasone | ||
|---|---|---|---|
| CAS Number | 378-44-9 | Molecular Weight | 392.461 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 568.2±50.0 °C at 760 mmHg |
| Molecular Formula | C22H29FO5 | Melting Point | 235-237°C |
| MSDS | ChineseUSA | Flash Point | 297.5±30.1 °C |
| Symbol | GHS08 | Signal Word | Danger |
Names
| Name | betamethasone |
|---|---|
| Synonym | More Synonyms |
Betamethasone BiologicalActivity
| Description | Betamethasone is a glucocorticoid steroid with anti-inflammatory and immunosuppressive properties.Target: Glucocorticoid ReceptorBetamethasone is a potent glucocorticoid steroid with anti-inflammatory and immunosuppressive properties. Unlike other drugs with these effects, betamethasone does not cause water retention. The median (range) IC50 value for betamethasone butyrate propionate evaluated in the streptococcal pyrogenic enterotoxin A-stimulated peripheral-blood mononuclear cells was 291.6 (0.001-1171.5) ng/ml, which was significantly higher than the value 0.072 (0.01-222.5) ng/ml found in concanavalin A-stimulated peripheral-blood mononuclear cells (P=0.0245) [1]. Children exposed prenatally to betamethasone (n = 121) did not differ in systolic or diastolic blood pressure from children exposed to placebo (n = 102) (mean difference: systolic: -1.6 mm Hg; 95% confidence interval: -4.1 to 0.8 mm Hg; diastolic: -0.3 mm Hg; 95% confidence interval: -2.5 to 1.8 mm Hg) [2]. Intra-articular corticosteroid injection of 6 mg of betamethasone acetate/betamethasone sodium phosphate at the knee joint was not significantly associated with SAI at the time points tested [3].Clinical indications: Dermatitis; Discoid lupus erythematosus; Eczema; Lichen; Prurigo; PsoriasisToxicity: Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Glucocorticoid ReceptorResearch Areas >>Inflammation/Immunology |
| References | [1]. Arai, K., et al., Comparative study of the effects of betamethasone butyrate propionate, vitamin D3 derivatives, and cyclosporine on human lymphocyte-proliferation stimulated with a hemolytic streptococci-derived superantigen. Eur J Pharmacol, 2007. 571(2-3): p. 222-30. [2]. Dalziel, S.R., et al., Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics, 2004. 114(3): p. e373-7. [3]. Habib, G., et al., The effect of intra-articular injection of betamethasone acetate/betamethasone sodium phosphate at the knee joint on the hypothalamic-pituitary-adrenal axis: a case-controlled study. J Investig Med, 2013. 61(7): p. 1104-7. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 568.2±50.0 °C at 760 mmHg |
| Melting Point | 235-237°C |
| Molecular Formula | C22H29FO5 |
| Molecular Weight | 392.461 |
| Flash Point | 297.5±30.1 °C |
| Exact Mass | 392.199890 |
| PSA | 94.83000 |
| LogP | 1.87 |
| Vapour Pressure | 0.0±3.5 mmHg at 25°C |
| Index of Refraction | 1.592 |
| InChIKey | UREBDLICKHMUKA-DVTGEIKXSA-N |
| SMILES | CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >4500 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 21,2117,1979 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 1200 ug/kg
- SEX/DURATION :
- female 18-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - other effects to embryo
- REFERENCE :
- PEREBL Pediatric Research. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1967- Volume(issue)/page/year: 33,5,1993
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 150 ug/kg
- SEX/DURATION :
- female 16-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - biochemical and metabolic
- REFERENCE :
- JPEMAO Journal of Perinatal Medicine. (Walter de Gruyter, Inc., 200 Saw Mill River Rd., Hawthorne, NY 10532) V.1- 1973- Volume(issue)/page/year: 22,319,1993
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 2 mg/kg
- SEX/DURATION :
- female 18-19 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - other effects
- REFERENCE :
- DPTHDL Developmental Pharmacology and Therapeutics. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 18,14,1992
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 600 ug/kg
- SEX/DURATION :
- female 20 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - other effects to embryo
- REFERENCE :
- AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 127,261,1977
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 1600 ug/kg
- SEX/DURATION :
- female 18 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - respiratory system
- REFERENCE :
- ARDSBL American Review of Respiratory Disease. (American Lung Assoc., 1740 Broadway, New York, NY 10019) V.80- 1959- Volume(issue)/page/year: 117,377,1978
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 1200 ug/kg
- SEX/DURATION :
- female 18-19 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Specific Developmental Abnormalities - hepatobiliary system
- REFERENCE :
- AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 133,677,1979
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 5200 ug/kg
- SEX/DURATION :
- female 16-18 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - endocrine system
- REFERENCE :
- AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 133,677,1979
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 69 mg/kg
- SEX/DURATION :
- female 8-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)
- REFERENCE :
- JIDOAA Experimental Animals. Jikken Dobutso Iho. (Nippon Jikken Dobutsu Gakkai, c/o Keio Gijuku Daigaku Igakubu Jikken Dobutsu Senta, 35 Shinano-machi, Shinjuku-ku, Tokyo 160, Japan) V.1- 1952- Volume(issue)/page/year: 35,387,1986
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 138 mg/kg
- SEX/DURATION :
- female 8-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death
- REFERENCE :
- JIDOAA Experimental Animals. Jikken Dobutso Iho. (Nippon Jikken Dobutsu Gakkai, c/o Keio Gijuku Daigaku Igakubu Jikken Dobutsu Senta, 35 Shinano-machi, Shinjuku-ku, Tokyo 160, Japan) V.1- 1952- Volume(issue)/page/year: 35,387,1986 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - M0622 No. of Facilities: 20 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 656 (estimated) No. of Female Employees: 489 (estimated)
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H360-H373 |
| Precautionary Statements | P201-P308 + P313 |
| Target Organs | Endocrine system, Kidney, Liver |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
| Hazard Codes | Xi,Xn |
| Risk Phrases | R40 |
| Safety Phrases | 22-36 |
| RIDADR | NONH for all modes of transport |
| RTECS | TU4000000 |
| HS Code | 2937229000 |
Customs
| HS Code | 2937229000 |
|---|
Articles116
More Articles| Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem. Res. Toxicol. 23 , 171-83, (2010) Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental... | |
| Convenient QSAR model for predicting the complexation of structurally diverse compounds with β-cyclodextrins Bioorg. Med. Chem. 17 , 896-904, (2009) This paper reports a QSAR study for predicting the complexation of a large and heterogeneous variety of substances (233 organic compounds) with beta-cyclodextrins (beta-CDs). Several different theoret... | |
| Developing structure-activity relationships for the prediction of hepatotoxicity. Chem. Res. Toxicol. 23 , 1215-22, (2010) Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals ... |
Synonyms
| 16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione |
| Bifas |
| Betasolon |
| (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one |
| Betadexamethasone |
| Celestene |
| Flubenisolone |
| Visubeta |
| 9A-FLUORO-16β-METHYLPREDNISOLONE |
| 9α-Fluoro-11β,17α,21-trihydroxy-16β-methyl-1,4-pregnadiene-3,20-dione |
| b-Methasone alcohol |
| Bebate |
| EINECS 206-825-4 |
| 16b-Methyl-9a-fluoroprednisolone |
| Celestone |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11β,17,21-trihydroxy-16β-methyl- |
| pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11b,16b)- |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16β)- |
| betamethazone |
| (11b,16b)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione |
| 9α-Fluoro-16β-methylprednisolone |
| Betametasona [INN-Spanish] |
| Betnelan |
| b-Methasone |
| β-Methasone |
| Betametasone [DCIT] |
| DERMABET |
| Pertene |
| UNII-9842X06Q6M |
| β-Methasone alcohol |
| MFCD00062969 |
| Betsolan |
| (11β,16β)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione |
| 4-08-00-03501 (Beilstein Handbook Reference) |
| Diprolene |
| Bedifos |
| Becort |
| Cidoten |
| Bentelan |
| β-Corlan |
| b-Corlan |
| 9α-Fluoro-16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione |
| 9a-Fluoro-16b-methylprednisolone |
| Betamethasone Solutiom |
| 6beta) |
| Betamethasone |
| Betalon |
| 16b-Methyl-9a-fluoro-D1-hydrocortisone |
